326 related articles for article (PubMed ID: 26159849)
21. Paclitaxel resistance in MCF-7/PTX cells is reversed by paeonol through suppression of the SET/phosphatidylinositol 3-kinase/Akt pathway.
Zhang W; Cai J; Chen S; Zheng X; Hu S; Dong W; Lu J; Xing J; Dong Y
Mol Med Rep; 2015 Jul; 12(1):1506-14. PubMed ID: 25760096
[TBL] [Abstract][Full Text] [Related]
22. Ursolic acid inhibits proliferation and reverses drug resistance of ovarian cancer stem cells by downregulating ABCG2 through suppressing the expression of hypoxia-inducible factor-1α in vitro.
Wang WJ; Sui H; Qi C; Li Q; Zhang J; Wu SF; Mei MZ; Lu YY; Wan YT; Chang H; Guo PT
Oncol Rep; 2016 Jul; 36(1):428-40. PubMed ID: 27221674
[TBL] [Abstract][Full Text] [Related]
23. HOXB4 knockdown enhances the cytotoxic effect of paclitaxel and cisplatin by downregulating ABC transporters in ovarian cancer cells.
Li Y; Sun J; Gao S; Hu H; Xie P
Gene; 2018 Jul; 663():9-16. PubMed ID: 29660518
[TBL] [Abstract][Full Text] [Related]
24. Silencing SOX2 Expression by RNA Interference Inhibits Proliferation, Invasion and Metastasis, and Induces Apoptosis through MAP4K4/JNK Signaling Pathway in Human Laryngeal Cancer TU212 Cells.
Yang N; Wang Y; Hui L; Li X; Jiang X
J Histochem Cytochem; 2015 Sep; 63(9):721-33. PubMed ID: 26001828
[TBL] [Abstract][Full Text] [Related]
25. CD24 expression is a marker for predicting clinical outcome and regulates the epithelial-mesenchymal transition in ovarian cancer via both the Akt and ERK pathways.
Nakamura K; Terai Y; Tanabe A; Ono YJ; Hayashi M; Maeda K; Fujiwara S; Ashihara K; Nakamura M; Tanaka Y; Tanaka T; Tsunetoh S; Sasaki H; Ohmichi M
Oncol Rep; 2017 Jun; 37(6):3189-3200. PubMed ID: 28440503
[TBL] [Abstract][Full Text] [Related]
26. Akt involvement in paclitaxel chemoresistance of human ovarian cancer cells.
Kim SH; Juhnn YS; Song YS
Ann N Y Acad Sci; 2007 Jan; 1095():82-9. PubMed ID: 17404021
[TBL] [Abstract][Full Text] [Related]
27. Cepharanthine hydrochloride reverses P‑glycoprotein-mediated multidrug resistance in human ovarian carcinoma A2780/Taxol cells by inhibiting the PI3K/Akt signaling pathway.
Huang CZ; Wang YF; Zhang Y; Peng YM; Liu YX; Ma F; Jiang JH; Wang QD
Oncol Rep; 2017 Oct; 38(4):2558-2564. PubMed ID: 28791369
[TBL] [Abstract][Full Text] [Related]
28. [Effects of siltuximab on the interleukin-6/Stat3 signaling pathway in ovarian cancer].
Guo YQ; Lu P; Duan ZF; Zhang Z
Zhonghua Fu Chan Ke Za Zhi; 2010 Nov; 45(11):854-9. PubMed ID: 21211286
[TBL] [Abstract][Full Text] [Related]
29. Attenuation of MUC4 potentiates the anticancer activity of auranofin via regulation of the Her2/Akt/FOXO3 pathway in ovarian cancer cells.
Bae JS; Lee J; Park Y; Park K; Kim JR; Cho DH; Jang KY; Park SH
Oncol Rep; 2017 Oct; 38(4):2417-2425. PubMed ID: 28765909
[TBL] [Abstract][Full Text] [Related]
30. Increased expression of MyD88 and association with paclitaxel resistance in breast cancer.
Xiang F; Ni Z; Zhan Y; Kong Q; Xu J; Jiang J; Wu R; Kang X
Tumour Biol; 2016 May; 37(5):6017-25. PubMed ID: 26596839
[TBL] [Abstract][Full Text] [Related]
31. Folic acid-coupled nano-paclitaxel liposome reverses drug resistance in SKOV3/TAX ovarian cancer cells.
Tong L; Chen W; Wu J; Li H
Anticancer Drugs; 2014 Mar; 25(3):244-54. PubMed ID: 24275314
[TBL] [Abstract][Full Text] [Related]
32. The effects of REG4 expression on chemoresistance of ovarian cancer.
Xiang LW; Xue H; Ha MW; Yu DY; Xiao LJ; Zheng HC
J Obstet Gynaecol; 2022 Oct; 42(7):3149-3157. PubMed ID: 35929918
[TBL] [Abstract][Full Text] [Related]
33. Mesothelin inhibits paclitaxel-induced apoptosis through the PI3K pathway.
Chang MC; Chen CA; Hsieh CY; Lee CN; Su YN; Hu YH; Cheng WF
Biochem J; 2009 Dec; 424(3):449-58. PubMed ID: 19747165
[TBL] [Abstract][Full Text] [Related]
34. Treatment with β-elemene combined with paclitaxel inhibits growth, migration, and invasion and induces apoptosis of ovarian cancer cells by activation of STAT-NF-κB pathway.
Xiaomeng F; Lei L; Jinghong A; Juan J; Qi Y; Dandan Y
Braz J Med Biol Res; 2020; 53(6):e8885. PubMed ID: 32401925
[TBL] [Abstract][Full Text] [Related]
35. CNOT7 modulates biological functions of ovarian cancer cells via AKT signaling pathway.
Yu J; Hu X; Chen X; Zhou Q; Jiang Q; Shi Z; Zhu H
Life Sci; 2021 Mar; 268():118996. PubMed ID: 33412213
[TBL] [Abstract][Full Text] [Related]
36. MiRNA-149 modulates chemosensitivity of ovarian cancer A2780 cells to paclitaxel by targeting MyD88.
Zhan Y; Xiang F; Wu R; Xu J; Ni Z; Jiang J; Kang X
J Ovarian Res; 2015 Jul; 8():48. PubMed ID: 26223974
[TBL] [Abstract][Full Text] [Related]
37. TLR5/7-mediated PI3K activation triggers epithelial-mesenchymal transition of ovarian cancer cells through WAVE3-dependent mesothelin or OCT4/SOX2 expression.
Park GB; Kim D
Oncol Rep; 2017 Nov; 38(5):3167-3176. PubMed ID: 28901470
[TBL] [Abstract][Full Text] [Related]
38. Notch3-specific inhibition using siRNA knockdown or GSI sensitizes paclitaxel-resistant ovarian cancer cells.
Kang H; Jeong JY; Song JY; Kim TH; Kim G; Huh JH; Kwon AY; Jung SG; An HJ
Mol Carcinog; 2016 Jul; 55(7):1196-209. PubMed ID: 26207830
[TBL] [Abstract][Full Text] [Related]
39. Sex determining region Y-box 2 inhibits the proliferation of colorectal adenocarcinoma cells through the mTOR signaling pathway.
Liu H; Du L; Wen Z; Yang Y; Li J; Dong Z; Zheng G; Wang L; Zhang X; Wang C
Int J Mol Med; 2013 Jul; 32(1):59-66. PubMed ID: 23599173
[TBL] [Abstract][Full Text] [Related]
40. Multifunctional Polymeric Micelles Co-loaded with Anti-Survivin siRNA and Paclitaxel Overcome Drug Resistance in an Animal Model of Ovarian Cancer.
Salzano G; Navarro G; Trivedi MS; De Rosa G; Torchilin VP
Mol Cancer Ther; 2015 Apr; 14(4):1075-84. PubMed ID: 25657335
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
